TSHA · Taysha Gene Therapies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $9.77M | $8.33M | $15.45M | $2.50M | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $86.40M | $66.00M | $56.78M | $91.17M | $131.94M | $31.89M |
| SG&A | $33.87M | $28.95M | $30.05M | $37.36M | $41.32M | $11.11M |
| Total Operating Expenses | $120.27M | $99.79M | $87.89M | $164.95M | $173.27M | $43.00M |
| D&A | $1.15M | $1.25M | $1.37M | $1.17M | $492.0K | $9.0K |
| Operating Income | ($110.50M) | ($91.46M) | ($72.44M) | ($162.45M) | ($173.27M) | ($43.00M) |
| Interest Expense | $63.0K | $102.0K | $5.00M | $3.80M | $1.43M | $28.0K |
| Income Tax | $0 | $0 | $0 | $0 | - | $0 |
| Net Income | ($109.00M) | ($89.30M) | ($111.57M) | ($166.01M) | ($174.52M) | ($60.01M) |
| EPS - Basic | ($0.34) | ($0.36) | ($0.96) | ($4.64) | - | - |
| EPS - Diluted | ($0.34) | ($0.36) | ($0.96) | ($4.64) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $319.77M | $139.04M | $143.94M | $87.88M | $149.10M | $251.25M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $6.28M | $3.59M | $6.37M | $10.95M | $21.76M | $1.99M |
| Current Assets | $324.65M | $142.13M | $149.87M | $96.42M | $159.60M | $257.88M |
| Total Assets | $343.32M | $160.36M | $172.73M | $126.28M | $213.96M | $258.88M |
| Current Liabilities | $26.55M | $26.23M | $36.76M | $62.79M | $51.75M | $7.13M |
| Long-term Debt | $50.11M | $43.94M | $40.51M | $37.97M | $37.19M | - |
| Total Liabilities | $96.38M | $88.84M | $97.79M | $125.33M | $118.57M | $7.58M |
| Stockholders' Equity | $246.94M | $71.53M | $74.94M | $949.0K | $95.38M | $251.30M |
| Retained Earnings | ($711.30M) | ($602.30M) | ($513.01M) | ($401.44M) | ($235.65M) | ($61.13M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($93.09M) | ($81.22M) | ($73.02M) | ($88.39M) | ($117.04M) | ($30.73M) |
| Investing Cash Flow | ($604.0K) | ($363.0K) | ($7.35M) | ($24.93M) | ($21.55M) | ($9.08M) |
| Financing Cash Flow | $274.59M | $76.68M | $136.39M | $52.10M | $39.08M | $291.06M |
| CapEx | $738.0K | $374.0K | $3.87M | $20.62M | $15.30M | $82.0K |
| Free Cash Flow | ($93.83M) | ($81.60M) | ($76.89M) | ($109.01M) | ($132.35M) | ($30.81M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -1130.6% | -1097.6% | -468.8% | -6492.7% | - | - |
| EBITDA margin | -1118.9% | -1082.6% | -460.0% | -6445.8% | - | - |
| Net margin | -1115.3% | -1071.6% | -722.1% | -6635.3% | - | - |
| Free cash flow margin | -960.1% | -979.2% | -497.6% | -4356.9% | - | - |
| FCF / Net income | 0.86 | 0.91 | 0.69 | 0.66 | 0.76 | 0.51 |
| R&D / Revenue | 884.1% | 792.0% | 367.5% | 3643.8% | - | - |
| SG&A / Revenue | 346.5% | 347.4% | 194.5% | 1493.2% | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -31.7% | -55.7% | -64.6% | -131.5% | -81.6% | -23.2% |
| Return on equity | -44.1% | -124.8% | -148.9% | -17493.6% | -183.0% | -23.9% |
| Return on invested capital | -29.4% | -62.6% | -49.6% | -329.8% | - | - |
| Liquidity | ||||||
| Current ratio | 12.23 | 5.42 | 4.08 | 1.54 | 3.08 | 36.17 |
| Quick ratio | 12.23 | 5.42 | 4.08 | 1.54 | 3.08 | 36.17 |
| Cash ratio | 12.04 | 5.30 | 3.92 | 1.40 | 2.88 | 35.24 |
| Leverage | ||||||
| Debt / Equity | 0.20 | 0.61 | 0.54 | 40.01 | 0.39 | - |
| Debt / Assets | 0.15 | 0.27 | 0.23 | 0.30 | 0.17 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1753.9x | -896.7x | -14.5x | -42.8x | -121.3x | -1535.8x |
| Equity multiplier | 1.39 | 2.24 | 2.31 | 133.06 | 2.24 | 1.03 |
| Liabilities / Assets | 0.28 | 0.55 | 0.57 | 0.99 | 0.55 | 0.03 |
| Efficiency | ||||||
| Asset turnover | 0.03 | 0.05 | 0.09 | 0.02 | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 7.1x | 6.1x | 2.7x | 89.7x | - | - |
| P / S | 179.9x | 51.9x | 13.3x | 34.0x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 17.3% | -46.1% | 517.5% | - | - | - |
| Revenue CAGR (3y) | 57.5% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -20.8% | -26.3% | 55.4% | 6.2% | -302.9% | - |
| Net income growth (YoY) | -22.1% | 20.0% | 32.8% | 4.9% | -190.8% | - |
| EPS growth (YoY) | 5.6% | 62.5% | 79.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -15.0% | -6.1% | 29.5% | 17.6% | -329.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 245.2% | -4.6% | 7796.4% | -99.0% | -62.0% | - |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-1.03
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Taysha Gene Therapies against the 5 most active filers in the same SIC group.